SJSonia Jain

Sonia Jain

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sonia Jain has a total of 500 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Associations of body composition and visceral adiposity with BMD and trabecular bone score in young adults with obesity

    by Horacio Sanchez-Trigo, David Wing, Shadia J Mansour-Assi, Jeanne F Nichols, Britta A Larsen, Borja Sañudo, Natalie M Yarish, Sonia Jain, Job G Godino

    Introduction: The skeletal relevance of body composition in young adults with overweight or obesity remains incompletely characterized. We examined associations of body mass index (BMI), weight-normalized lean mass, weight-normalized total fat mass, and weight-normalized dual-energy X-ray absorptiometry (DXA)-estimated visceral adipose tissue mass with bone mineral density (BMD) and trabecular bone score (TBS). Methods: Cross-sectional baseline data from 638 participants (aged 18–35 years, BMI ≥25 and <40 kg/m²) in the SMART 2.0 study were analyzed. DXA assessed body composition and BMD; TBS was calculated with TBS iNsight® v3. Separate age- and sex-adjusted linear models used standardized predictors and HC3-robust inference. Results: BMI was positively associated with femoral neck BMD (β=0.0379; 95% CI: 0.028, 0.048), total hip BMD, and lumbar spine BMD, but inversely associated with mean TBS (β=−0.0179; 95% CI: −0.025, −0.011). Weight-normalized lean mass was positively associated with all outcomes, including TBS (β=0.0336; 95% CI: 0.024, 0.043). Weight-normalized total fat mass and weight-normalized DXA-estimated visceral adipose tissue mass were inversely associated with all outcomes; for visceral adiposity and TBS, β=−0.0321 (95% CI: −0.039, −0.025). Absolute total fat mass was positively associated with hip BMD but inversely associated with TBS. Conclusions: BMI and body-composition measures showed differing associations with BMD and TBS. Given the cross-sectional design, body-size-related TBS missingness, and potential adiposity-related measurement artifacts, findings are hypothesis-generating and do not establish impaired bone microarchitecture.

  • Open Access

    The CBI-M framework for characterization of traumatic brain injury: Evaluation of performance using data from the CENTER-TBI and TRACK-TBI prospective cohort studies

    by Dana Pisică, Ana Mikolić, John K. Yue, Michael A. McCrea, Kristen Dams-O’COnnor, Véronique De Keyser, Sonia Jain, Amy J. Markowitz, David K. Menon, Virginia Newcombe, et al.

    Background: The CBI-M Framework, incorporating Clinical, Biomarker, Imaging, and Modifier pillars, was recently proposed to provide a comprehensive characterization of patients with acute traumatic brain injury (TBI). Such detailed characterization reflects the clinical and biological heterogeneity of TBI, and is considered essential to inform appropriate clinical management. Still unclear is the extent to which CBI-M captures clinically relevant heterogeneity in relation to diagnosis, clinical care pathways, and longer-term outcome. Prior to broad implementation into clinical practice and research, its diagnostic and prognostic performance needs to be ascertained. In this study, we aim to explore how CBI-M and its constituent pillars relate to diagnosis, clinical care pathways, and outcome in two large contemporary TBI cohorts. Methods and findings: We analyzed data of patients with acute TBI enrolled in the European-based CENTER-TBI ( N = 4,509) and US-based TRACK-TBI ( N = 2,552) prospective observational studies. We assessed associations of the CBI-M Framework, its pillars, and pillar components with key clinical endpoints: diagnosis (traumatic intracranial injury on computed tomography); care pathways (hospital admission, intensive care admission, intracranial pressure monitoring, and major cranial surgery); and outcomes at 6 months post-injury (mortality, Glasgow Outcome Scale-Extended (GOSE), and health-related quality of life (HRQoL)). Discriminatory performance was calculated using the AUC and explained variability expressed with Nagelkerke’s pseudo-R 2 . Prognostic performance was compared to the established IMPACT-Lab and CRASH-CT prediction models in their respective target populations. For diagnostic and care path endpoints full CBI-M models achieved excellent discrimination (AUC CENTER-TBI: from 0.83 to 0.95; TRACK-TBI: from 0.88 to 0.98), and high proportions of explained variability (pseudo-R 2 CENTER-TBI: from 0.41 to 0.72; TRACK-TBI: from 0.55 to 0.80). Contributions of individual pillars varied by endpoint, with the Biomarker pillar contributing most for CT-defined abnormalities and the Imaging pillar to major cranial surgery. For mortality and unfavorable outcome (GOSE ≤ 4) similarly strong performance was observed: CENTER-TBI: AUC 0.89 (95% Confidence intervals (CI) [0.88,0.90]) and 0.92 (95% CI [0.91,0.94]) respectively; pseudo-R 2 0.53 (95% CI [0.50,0.57]) and 0.55 (95% CI [0.51,0.59]) respectively; TRACK-TBI: AUC 0.91 (95% CI [0.89,0.93]) and 0.95 (95% CI [0.93,0.97]) respectively; pseudo-R 2 0.57 (95% CI [0.52,0.62] and 0.57 (95% CI [0.50, 0.64] respectively), whereas performance for HRQoL was modest. Compared to the IMPACT-Lab and CRASH-CT models in their respective target populations, pseudo-R 2 values suggest that the full CBI-M model was more strongly associated with 6-month mortality and unfavorable outcomes. Methodological limitations include the restriction to analysis of data from high-income settings, limiting generalizability, the absence of three elements of the modifier pillar in the datasets accessed, and risk of possible reverse causality in some analyses. Conclusions: CBI-M provides a robust multimodal characterization of acute TBI that aligns closely with clinical decision-making and outcomes. Further prospective validation and optimization are justified and needed to inform implementation of the CBI-M Framework in clinical practice and research.

  • Open Access

    Risk Factors for Coronary Artery Aneurysms in Children With Kawasaki Disease

    by Shoko Yamazaki, Koichi Miyata, Xiaoying Sun, Chisato Shimizu, Ryusuke Ae, Kirsten B. Dummer, Adriana H. Tremoulet, Jane C. Burns, Sonia Jain

    Background: Coronary artery aneurysm (CAA) remains the most serious cardiovascular complication of Kawasaki disease. We sought to identify consistent risk factors for CAA among large contemporary cohorts from Japan and the United States. Methods: We conducted a retrospective cohort study including 42 350 children from the 26th and 27th Japanese Nationwide Kawasaki Disease Surveys (2019–2022) and 1216 children from a multiethnic US cohort. Multivariable logistic regression was used to evaluate associations between clinical variables and CAA at 1 month after disease onset ( Z score ≥2.5). Results: In both cohorts, baseline coronary artery dilation at diagnosis ( Z score ≥2.5) was strongly associated with CAA 1 month after disease onset (Japan: odds ratio [OR], 22.7 [95% CI, 19.2–26.7]; United States: OR, 13.4 [95% CI, 8.6–21.0]). Age younger than 6 months and intravenous immunoglobulin resistance were also independently associated with increased risk. These associations were also observed for medium to giant CAAs. Stratified analyses demonstrated that intravenous immunoglobulin resistance was most strongly associated with subsequent CAA among children with normal coronary arteries at diagnosis. Conclusions: Among large Japanese and US cohorts, coronary artery dilation at diagnosis and age younger than 6 months were consistent predictors of CAA. These associations were also observed for medium to giant CAA, underscoring their relevance for clinically significant coronary outcomes. Early coronary artery assessment provides important prognostic information and may inform cardiovascular risk stratification and management in children with Kawasaki disease.

  • Characterizing Time Toxicity in Lung Cancer Clinical Trials: Development and Application of a Novel Time Burden Metric

    by Amanda Herrmann, Sonia Jain, Lisa Madlensky, Lyudmila Bazhenova

    PURPOSE: Participation in clinical trials imposes additional time commitments beyond routine care; however, trial-associated time toxicity (TT) remains underinvestigated and poorly characterized. The purpose of this study was to develop a scalable, procedure-based metric to quantify total time required for trial participation using the protocol schedule of events. We applied this framework to lung cancer clinical trials to estimate trial-associated burden and explore changes in TT over time. MATERIALS AND METHODS: Protocols for clinical trials associated with United States (US) Food and Drug Administration (FDA) approvals of oral lung cancer therapies were obtained from public sources. Using each protocol's schedule of events, study-mandated procedures were assigned time toxicity units (TTUs) based on standardized time estimates. TTUs for each procedure were multiplied by their frequency and summed for screening through cycle 5 to determine a trial's total time toxicity (TTT). Days with health care contact (DHC) were summed over the same period to determine total DHC (TDHC). Median (m) TTT and TDHC were compared between studies published in 2005-2014 and 2015-2024 to assess temporal trends. Two-sample Mann-Whitney U tests were used for nonparametric comparisons. RESULTS: Thirty-two phase-specific protocols from trials published between 2005 and 2024 were included. Among studies published in 2005-2014 (n = 7), the median TTT (mTTT) was 63.8 (41.8-109.3) versus 82 (50.3-139.5) in 2015-2024 (n = 25) ( P = .042). Corresponding median TDHC values were 14 (10-21) versus 15 (11-44), respectively ( P = .16). CONCLUSION: More contemporary studies demonstrated higher TTT, with significantly greater mTTT observed in studies published in 2015-2024 versus 2005-2014. TDHC demonstrated less sensitivity in capturing differences in time burden. These findings demonstrate the feasibility and practical applicability of the proposed TT framework for characterizing protocol-associated time burden. Prospective validation and broader implementation may help inform patients and encourage streamlined protocol development.

  • Obstructive sleep apnea-related hypoxemia and heart rate dynamics are associated with systemic inflammation in people living with HIV

    by Alexia N. Perryman, Jorge A. Masso-Silva, Jeremy E. Orr, Xiaoying Sun, Sonia Jain, Pamela N. DeYoung, Brynn Norby, Sonia Ancoli-Israel, Atul Malhotra, Igor Grant, et al.

  • Open Access

    Normal Imaging and Biomarkers Do Not Preclude Poor Outcomes in Clinical TBI: A TRACK-TBI Study

    by Debbie Madhok, John K. Yue, Rebekah Mannix, Samuel A. McLean, Robert M. Rodríguez, Sonia Jain, Xiaoying Sun, Lindsay Nelson, Geoffrey T. Manley, Frederick K. Korley

    Background: Outcomes after mild traumatic brain injury (mTBI) without neuroimaging or blood biomarker abnormalities are poorly characterized. We evaluated 6-month outcomes in this population. Methods: We analyzed prospective TRACK-TBI data from 18 US Level I trauma centers between 2014 and 2018. Participants aged 17 years or older presented within 24 hours of injury with a Glasgow Coma Scale score of 15 and clinical signs of mTBI. Patients with negative head CT and MRI and non-elevated glial fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1 concentrations (CT−/MRI−/BNE) were compared with patients who had positive imaging or elevated biomarkers and with orthopedic trauma controls. The primary outcome was incomplete functional recovery at 6 months, defined as a Glasgow Outcome Scale–Extended score below 8. Secondary outcomes were persistent post-concussive symptoms, psychological distress, and impaired quality of life. Findings: We included 578 patients with mTBI (98 CT−/MRI−/BNE and 480 imaging-positive or biomarker-positive) and 168 orthopedic controls. In the CT−/MRI−/BNE group, median age was 27.5 years and 54% were male. At 6 months, 65% had incomplete all-cause functional recovery, 43% had persistent post-concussive symptoms, 30% had psychological distress, and 37% had impaired quality of life. Outcomes were similar to or worse than those in imaging-positive or biomarker-positive patients and worse than those in orthopedic controls. Pre-injury psychiatric history was associated with incomplete TBI-attributable recovery (adjusted odds ratio [aOR] 3.2, 95% CI 1.2–9.1), persistent symptoms (3.1, 1.1–8.4), psychological distress (7.2, 2.1–24.0), and impaired quality of life (9.3, 2.9–30.0). Interpretation: Negative CT, MRI, and acute blood biomarker findings do not identify a uniformly low-risk mTBI population. Pre-injury psychiatric history could inform emergency-department risk stratification and targeted post-discharge follow-up.

  • Combat injury, pain, and suicidal ideation in U.S. army service members and veterans

    by Marcus G. Wild, Laura Campbell-Sills, Xiaoying Sun, Ronald C. Kessler, James Wagner, David M. Benedek, Robert J. Ursano, Sonia Jain, Murray B. Stein

  • Open Access

    The SMART-of-1 approach to personalized treatment trials

    by Yuwei Cheng, Sonia Jain

    Adapting treatments to individual patient attributes has become essential in personalized healthcare, especially for managing complex and variable chronic diseases. Despite their important role in precision medicine, traditional N-of-1 trials face design challenges related to carryover effects, washout periods, and blinding. To address these limitations, we propose a novel design, which we call SMART-of-1, that incorporates elements from a small sample Sequential, Multiple Assignment Randomized Trials (snSMART) into the N-of-1 trial. This innovative approach is tailored for comparative effectiveness studies in chronic diseases with acute presentations, such as asthma and sleep disorders. We propose a Bayesian joint stage individual model and a Bayesian hierarchical model for SMART-of-1 trials to estimate both individual treatment effects and population-level effects in a combined final analysis. In addition, the within-cycle tailored sequences of treatments can be assessed in the binary outcome setting. Two case studies, a fatigue study and a sleep study, are presented to demonstrate the improved accuracy and efficiency of the SMART-of-1 design for different types of endpoints. In the fatigue study with a continuous endpoint, we demonstrate that both the estimated individual and aggregated treatment effects from the SMART-of-1 trials have improved efficiency in terms of bias and rMSE compared to a standard N-of-1 trial. Simulations from the sleep study indicate the improved estimation of cycle-wise dynamic treatment regimen (DTR) effects for the SMART-of-1 model compared to a conventional snSMART approach, particularly in the presence of heterogeneity among individual treatment effects.

  • Ocular Hypertension Treatment Study: Effect of Time After Incident Glaucoma on OCT Optic Nerve Head and Macula Measurements

    by Evan Walker, Christopher Bowd, Sonia Jain, Julia Huecker, Keri A. Dirkes, Suzanne Vega, Maria Hunsicker, Mae O. Gordon, Michael A. Kass, Robert N. Weinreb, et al.


  • Open Access

    Combat injury, pain, and mental health outcomes in US Army service members

    by Marcus G. Wild, Laura Campbell-Sills, Xiaoying Sun, Ronald C. Kessler, David M. Benedek, Robert J. Ursano, Sonia Jain, Murray B. Stein

    Background: The impact of combat injury on the development of chronic pain and mental health concerns in combat-exposed populations is unknown. This study examined associations of combat injury and injury–related pain with pain-related factors and mental health outcomes, and potential mediation of the relation between combat injury and mental health outcomes by pain-related factors. Methods: Pain interference, pain catastrophizing, pain intensity, post-traumatic stress disorder (PTSD), and major depressive episode (MDE) were assessed in (1) a probability sample of US Army soldiers and veterans cross-sectionally and (2) US Army soldiers before and 1, 3, and 9 months after deployment to Afghanistan. Associations among these variables were modeled using logistic regression and multiple mediation analyses. Results: Among 5003 service members with cross-sectional data, combat injury–related pain was associated with increased odds of clinically significant pain intensity (OR=2.69), pain interference (OR=3.69), MDE (OR=2.17), and PTSD (OR=3.96) relative to pain from other injuries and conditions. Among 4645 service members assessed pre- and post-deployment, combat injury was associated with increased odds of new-onset pain interference (OR=2.78), pain catastrophizing (OR=2.75), PTSD (OR=4.06), and MDE (OR=2.56) 3 months post-deployment, and PTSD (OR=2.86) and MDE (OR=1.74) 9 months post-deployment. Pain-related factors mediated the relations of combat injury with post-deployment PTSD and MDE. Conclusions: Combat injury is associated with greater odds of pain interference, pain catastrophizing, PTSD, and MDE compared to other sources of pain in a cohort of US service members. Efforts to address pain-related factors following combat injury may mitigate the risk of subsequent chronic pain and mental health disorders.